Inogen CFO Departs, Interim Appointed

Ticker: INGN · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1294133

Inogen Inc 8-K Filing Summary
FieldDetail
CompanyInogen Inc (INGN)
Form Type8-K
Filed DateJul 31, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: management-change, cfo-departure

Related Tickers: INGN

TL;DR

Inogen's CFO is OUT, interim is IN. Watch this space.

AI Summary

Inogen Inc. announced on July 26, 2024, the departure of its Chief Financial Officer, Michael T. Flannery, effective immediately. The company has appointed Paul J. Hamann as interim CFO. Inogen Inc. is a Delaware-based company specializing in orthopedic, prosthetic, and surgical appliances and supplies.

Why It Matters

A sudden CFO departure can signal internal issues or financial concerns, potentially impacting investor confidence and the company's stock performance.

Risk Assessment

Risk Level: medium — CFO departures can indicate underlying financial or operational issues, creating uncertainty for investors.

Key Players & Entities

  • Inogen Inc. (company) — Registrant
  • Michael T. Flannery (person) — Departing Chief Financial Officer
  • Paul J. Hamann (person) — Interim Chief Financial Officer
  • July 26, 2024 (date) — Effective date of CFO departure
  • Delaware (jurisdiction) — State of Incorporation

FAQ

Who has been appointed as the interim Chief Financial Officer of Inogen Inc.?

Paul J. Hamann has been appointed as the interim Chief Financial Officer of Inogen Inc.

When was Michael T. Flannery's departure as CFO effective?

Michael T. Flannery's departure as CFO was effective immediately as of July 26, 2024.

What is the exact name of the company filing this report?

The exact name of the company is Inogen, Inc.

In which state is Inogen, Inc. incorporated?

Inogen, Inc. is incorporated in Delaware.

What is the SIC code for Inogen Inc.?

The Standard Industrial Classification (SIC) code for Inogen Inc. is 3842, which pertains to Orthopedic, Prosthetic & Surgical Appliances & Supplies.

Filing Stats: 635 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-07-31 17:05:58

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value INGN The Nasdaq Stock Mar

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Transition Agreement and Release by and between the Company and Jason M. Somer, dated July 26, 2024. 104 The cover page of this Current Report on Form 8-K, formatted in inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOGEN, INC. Date: July 31, 2024 By: /s/ Michael Bourque Michael Bourque Executive Vice President Chief Financial Officer Treasurer (Principal Accounting and Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.